Clinical Significance And Brain Injury

  • Hypoglycemia is the most frequent metabolic abnormality encountered in the neonatal period.
  • Glucose provides the predominant energy substrate for the neonatal brain, accounting for nearly 90% of total oxygen consumption in early infancy.
  • Severe, recurrent, or prolonged hypoglycemia causes neuronal injury primarily in the superficial cerebral cortex, parieto-occipital white matter, and basal ganglia.
  • Long-term sequelae include cortical visual impairment, occipital lobe epilepsy, developmental delay, and cerebral palsy.

40% Dextrose Gel (Sugar Babies Trial)

  • Sugar Babies Study (Lancet 2013):
    • Randomized, double-blind, placebo-controlled trial evaluating 40% dextrose gel ($200\text{ mg/kg}$ or $0.5\text{ mL/kg}$) massaged into the buccal mucosa alongside milk feeds for late preterm and term infants with asymptomatic hypoglycemia.
    • Findings: Treatment failure was halved (RR 0.73), and NICU admissions for hypoglycemia were reduced by nearly half (14% vs 25%, RR 0.54, $p=0.002$).
    • Exclusive breastfeeding rates at hospital discharge were significantly improved.
    • Follow-up at 2 and 4.5 years demonstrated neurodevelopmental safety and equivalent cognitive outcomes compared to standard care.
  • Pre-hPOD Trial (NEJM 2021): Evaluated prophylactic 40% dextrose gel given shortly after birth in at-risk neonates (infants of diabetic mothers, preterm, SGA, LGA) and showed a significant reduction in subsequent hypoglycemia episodes without adverse effects.

Administration Protocol For Dextrose Gel

  • Indicated for asymptomatic hypoglycemia in late preterm and term infants who can suck.
  • Dose: 0.5 mL/kg of 40% dextrose gel (providing 200 mg/kg of glucose).
  • Dry the infant's buccal mucosa with sterile gauze.
  • Using a gloved finger, massage half of the measured dose into each buccal cheek.
  • Encourage immediate breastfeeding or give expressed breast milk by spoon or paladai right after gel application.
  • Recheck blood glucose 30 minutes after gel administration and feeding.
  • A maximum of 6 doses can be given in the first 48 hours (maximum 2 consecutive doses for any single hypoglycemic episode before starting intravenous fluids).

Operational Thresholds (AAP vs PES vs BAPM)

AuthorityPostnatal AgeOperational ThresholdClinical Action
AAP (American Academy of Pediatrics)0 to 4 hours<25 mg/dL (1.4 mmol/L)Feed + gel; if <25 mg/dL persists, start IV glucose
<35 mg/dL (1.9 mmol/L)If <35 mg/dL persists after re-feed, start IV glucose
4 to 24 hours<35 mg/dL (1.9 mmol/L)Feed + gel; start IV glucose if refractory
Target: $\ge 45\text{ mg/dL}$Pre-prandial target before next feed
>24 hoursTarget: $\ge 45\text{ to }50\text{ mg/dL}$Maintain throughout transitional phase
PES (Pediatric Endocrine Society)First 48 hoursTarget: $\mathbf{\ge 50\text{ mg/dL}}$Target to prevent neuroglycopenia
Beyond 48 hoursTarget: $\mathbf{\ge 60\text{ mg/dL}}$Target $\ge 70\text{ mg/dL}$ if hyperinsulinism suspected
BAPM (British Association)Any age<18 mg/dL (1.0 mmol/L)Urgent IV bolus + maintenance glucose infusion
Any age18 to 36 mg/dL (1.0 to 2.0 mmol/L)Gel + feed trial; if symptomatic, start IV fluids

Continuous Glucose Monitoring (CGM) In Neonates

  • Interstitial glucose sensors (such as Dexcom G6/G7) are increasingly utilized in VLBW and hyperinsulinemic neonates.
  • Continuous monitoring reveals that 30% to 40% of high-risk infants have asymptomatic, silent glycemic dips that are completely missed by intermittent heel-stick glucometer testing.
  • Real-time alarms help alert nursing staff before severe neuroglycopenia occurs.

Hyperinsulinemic Hypoglycemia Management

  • Suspected when the required glucose infusion rate (GIR) exceeds 10 to 12 mg/kg/minute.
  • Draw a critical blood sample during an episode of hypoglycemia (blood glucose <50 mg/dL):
    • Serum insulin and C-peptide (inappropriately detectable or elevated).
    • Cortisol and growth hormone (to rule out hypopituitarism/adrenal failure).
    • Free fatty acids and beta-hydroxybutyrate (suppressed in hyperinsulinism).
    • Urine ketones (absent in hyperinsulinism).

Medical Therapy

  • Diazoxide (First-Line):
    • Dose: 5 to 15 mg/kg/day orally in 2 to 3 divided doses.
    • Mechanism: Opens beta-cell $K_{\text{ATP}}$ channels, inhibiting calcium entry and suppressing insulin secretion.
    • Always co-prescribe Chlorothiazide (7 to 10 mg/kg/day) to prevent sodium retention, congestive heart failure, and pulmonary hypertension.
  • Octreotide (Second-Line):
    • Dose: 5 to 40 mcg/kg/day subcutaneously or via IV infusion.
    • Mechanism: Somatostatin analogue inhibiting insulin secretion via SSTR-5 receptors.
    • Monitor for tachyphylaxis and necrotizing enterocolitis (NEC).
  • $^{18}F\text{-DOPA PET-CT Scan}$: Used to differentiate focal adenomatous hyperplasia from diffuse $K_{\text{ATP}}$ channel mutations, allowing curative focal surgical pancreatectomy.

Bedside Glucose Infusion Calculations

$$\text{GIR (mg/kg/min)} = \frac{\% \text{ Dextrose} \times \text{Infusion Rate (mL/kg/day)}}{144}$$
  • In an emergency (symptomatic hypoglycemia or blood glucose <25 mg/dL), administer an IV mini-bolus of 2 mL/kg of 10% Dextrose (200 mg/kg) over 5 minutes.
  • Follow immediately with a continuous IV glucose infusion starting at 6 to 8 mg/kg/minute.
  • Titrate by 1 to 2 mg/kg/minute every 15 to 30 minutes based on repeat blood glucose checks.
  • Do not exceed 12.5% dextrose via peripheral IV lines; place an umbilical venous line or PICC if higher dextrose concentrations are needed.